Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IMPL Stock Summary
In the News
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.
IMPL Financial details
IMPL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.05 | 0.54 | |
Net income per share | -3.19 | -3.49 | -5.24 | -5.52 | |
Operating cash flow per share | -2.78 | -2.98 | -4.55 | -3.99 | |
Free cash flow per share | -2.89 | -3.12 | -4.57 | -4.05 | |
Cash per share | 2.82 | 0.54 | 6.04 | 2.59 | |
Book value per share | -6.98 | -10.16 | 3.6 | -1.88 | |
Tangible book value per share | -6.98 | -10.16 | 3.6 | -1.88 | |
Share holders equity per share | -6.98 | -10.16 | 3.6 | -1.88 | |
Interest debt per share | 0 | 0.64 | 2.02 | 2.77 | |
Market cap | 197.08M | 197.08M | 126M | 87.92M | |
Enterprise value | 160.08M | 198.4M | 67.24M | 78.45M | |
P/E ratio | -4.71 | -4.3 | -1.65 | -0.68 | |
Price to sales ratio | 0 | 0 | 188.62 | 6.95 | |
POCF ratio | -5.4 | -5.03 | -1.9 | -0.94 | |
PFCF ratio | -5.19 | -4.81 | -1.89 | -0.93 | |
P/B Ratio | -2.15 | -1.48 | 2.4 | -1.99 | |
PTB ratio | -2.15 | -1.48 | 2.4 | -1.99 | |
EV to sales | 0 | 0 | 100.66 | 6.2 | |
Enterprise value over EBITDA | -3.92 | -4.48 | -0.94 | -0.94 | |
EV to operating cash flow | -4.39 | -5.06 | -1.01 | -0.84 | |
EV to free cash flow | -4.21 | -4.84 | -1.01 | -0.83 | |
Earnings yield | -0.21 | -0.23 | -0.61 | -1.47 | |
Free cash flow yield | -0.19 | -0.21 | -0.53 | -1.08 | |
Debt to equity | 0 | -0.06 | 0.56 | -1.16 | |
Debt to assets | 0 | 0.7 | 0.3 | 0.58 | |
Net debt to EBITDA | 0.91 | -0.03 | 0.82 | 0.11 | |
Current ratio | 4.75 | 0.78 | 5.93 | 3.6 | |
Interest coverage | 0 | 0 | 0 | -6.01 | |
Income quality | 0.87 | 0.86 | 0.87 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 76.2 | 6.16 | |
Research and developement to revenue | 0 | 0 | 30.78 | 0.91 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.05 | 0.01 | 0.01 | |
Capex to revenue | 0 | 0 | -0.61 | -0.11 | |
Capex to depreciation | -2.11 | -1.65 | -0.38 | -1.15 | |
Stock based compensation to revenue | 0 | 0 | 4.69 | 0.41 | |
Graham number | 22.37 | 28.23 | 20.6 | 15.3 | |
ROIC | 0.45 | 0.36 | -0.87 | -9.99 | |
Return on tangible assets | -0.99 | -3.8 | -0.78 | -1.46 | |
Graham Net | -7.38 | -10.53 | 3.1 | -2.66 | |
Working capital | 31.2M | -2.35M | 78.62M | 57.65M | |
Tangible asset value | -91.7M | -133.5M | 52.51M | -44.16M | |
Net current asset value | -94.44M | -137.39M | 49.17M | -52.9M | |
Invested capital | 0 | -0.06 | 0.56 | -1.16 | |
Average receivables | 0 | 215K | 790.5K | 4.4M | |
Average payables | 0 | 3.52M | 5.34M | 6.23M | |
Average inventory | 0 | -215K | 1.3M | 5.63M | |
Days sales outstanding | 0 | 0 | 738.74 | 214.75 | |
Days payables outstanding | 0 | 0 | 3.36K | 342.35 | |
Days of inventory on hand | 0 | 0 | 1.49K | 473.57 | |
Receivables turnover | 0 | 0 | 0.49 | 1.7 | |
Payables turnover | 0 | 0 | 0.11 | 1.07 | |
Inventory turnover | 0 | 0 | 0.24 | 0.77 | |
ROE | 0.46 | 0.34 | -1.46 | 2.93 | |
Capex per share | -0.12 | -0.14 | -0.03 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.13 | 0.21 | 0.18 | 0.28 | 0.21 | |
Net income per share | -1.73 | -1.53 | -1.63 | -0.31 | -0.58 | |
Operating cash flow per share | -0.96 | -0.76 | -1.02 | -0.86 | -0.7 | |
Free cash flow per share | -0.96 | -0.8 | -1.06 | -0.86 | -0.74 | |
Cash per share | 3.36 | 2.56 | 1.49 | 0.64 | 0.01 | |
Book value per share | -0.94 | -1.86 | -3.07 | -3.33 | -3.87 | |
Tangible book value per share | -0.94 | -1.86 | -3.07 | -3.33 | -3.87 | |
Share holders equity per share | -0.94 | -1.86 | -3.07 | -3.33 | -3.87 | |
Interest debt per share | 1.99 | 2.87 | 2.1 | 2.08 | 4.68 | |
Market cap | 115.47M | 89.02M | 33.24M | 30.16M | 10.21M | |
Enterprise value | 86.03M | 79.55M | 50.68M | 67.29M | 124.77M | |
P/E ratio | -0.7 | -0.61 | -0.22 | -1.02 | -0.18 | |
Price to sales ratio | 37.46 | 17.78 | 7.6 | 4.58 | 2.03 | |
POCF ratio | -5.09 | -4.95 | -1.38 | -1.48 | -0.62 | |
PFCF ratio | -5.06 | -4.69 | -1.32 | -1.49 | -0.58 | |
P/B Ratio | -5.18 | -2.02 | -0.46 | -0.38 | -0.11 | |
PTB ratio | -5.18 | -2.02 | -0.46 | -0.38 | -0.11 | |
EV to sales | 27.91 | 15.89 | 11.59 | 10.22 | 24.84 | |
Enterprise value over EBITDA | -4.05 | -4.36 | -2.36 | -4.18 | -9.74 | |
EV to operating cash flow | -3.79 | -4.42 | -2.1 | -3.29 | -7.55 | |
EV to free cash flow | -3.77 | -4.19 | -2.01 | -3.31 | -7.14 | |
Earnings yield | -0.35 | -0.41 | -1.16 | -0.24 | -1.35 | |
Free cash flow yield | -0.2 | -0.21 | -0.76 | -0.67 | -1.71 | |
Debt to equity | -2.26 | -1.16 | -0.73 | -0.66 | -1.25 | |
Debt to assets | 0.48 | 0.58 | 0.82 | 1.17 | 3.27 | |
Net debt to EBITDA | 1.39 | 0.52 | -0.81 | -2.31 | -8.94 | |
Current ratio | 4.97 | 3.6 | 2.33 | 0.27 | 0.19 | |
Interest coverage | 6.65 | -1.07 | 7.83 | 5.34 | 3.5 | |
Income quality | 0.73 | 0.78 | 0.8 | 2.78 | 1.2 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.38 | 4.06 | 5.04 | 2.93 | 3.06 | |
Research and developement to revenue | 1.02 | 0.14 | 0.69 | 0.03 | 0.05 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.06 | 0.04 | -0.01 | 0.06 | |
Capex to revenue | -0.05 | -0.2 | -0.24 | 0.02 | -0.19 | |
Capex to depreciation | -0.51 | -3.31 | -3.85 | -2.32 | -1.51 | |
Stock based compensation to revenue | 0.18 | 0.25 | 0.3 | 0.17 | 0.21 | |
Graham number | 6.04 | 8 | 10.6 | 4.82 | 7.12 | |
ROIC | -0.9 | -2.83 | 1.94 | 1.02 | -0.46 | |
Return on tangible assets | -0.39 | -0.41 | -0.6 | -0.16 | -0.39 | |
Graham Net | -1.64 | -2.62 | -3.94 | -4.22 | -4.98 | |
Working capital | 79.31M | 57.65M | 29.6M | -88.32M | -101.32M | |
Tangible asset value | -22.29M | -44.16M | -72.91M | -79.16M | -91.91M | |
Net current asset value | -28.19M | -52.9M | -85.75M | -91.06M | -103.55M | |
Invested capital | -2.26 | -1.16 | -0.73 | -0.66 | -1.25 | |
Average receivables | 5.47M | 6.79M | 6.86M | 6.55M | 6.7M | |
Average payables | 4.75M | 5.42M | 6.11M | 4.8M | 3.6M | |
Average inventory | 7.78M | 8.52M | 8.22M | 7.5M | 6.92M | |
Days sales outstanding | 178.98 | 133.78 | 129.28 | 93.14 | 118.11 | |
Days payables outstanding | 283.55 | 247.31 | 241.56 | 96.65 | 150.7 | |
Days of inventory on hand | 514.58 | 342.1 | 315.65 | 195.23 | 277.02 | |
Receivables turnover | 0.5 | 0.67 | 0.7 | 0.97 | 0.76 | |
Payables turnover | 0.32 | 0.36 | 0.37 | 0.93 | 0.6 | |
Inventory turnover | 0.17 | 0.26 | 0.29 | 0.46 | 0.32 | |
ROE | 1.84 | 0.82 | 0.53 | 0.09 | 0.15 | |
Capex per share | -0.01 | -0.04 | -0.04 | 0.01 | -0.04 |
IMPL Frequently Asked Questions
What is Impel NeuroPharma, Inc. stock symbol ?
Impel NeuroPharma, Inc. is a US stock , located in Seattle of Wa and trading under the symbol IMPL
What is Impel NeuroPharma, Inc. stock quote today ?
Impel NeuroPharma, Inc. stock price is $0.04 today.
Is Impel NeuroPharma, Inc. stock public?
Yes, Impel NeuroPharma, Inc. is a publicly traded company.